A Study of BMS-986148 in Patients With Select Advanced Solid Tumors

Phase 1/2 Terminated 126 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986148 administered alone and in combination with nivolumab in patients with mesothelioma, non-small cell lung cancer, ovarian cancer, pancreatic cancer and gastric cancer.

Timeline

Start: 2015-06-19
Primary completion: 2019-02-25
Completion: 2020-05-07

Outcome

Outcome not reported

Stopped (Business): “Study terminated for business reasons not related to safety.”

Publications

Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS. Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Jan 1;28(1):95-105. doi: 10.1158/1078-0432.CCR-21-1181. Epub 2021 Oct 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986148	Unknown	0.1 mg/kg	Intravenous
Subject	BMS-986148	Unknown	0.4 mg/kg	Intravenous
Subject	BMS-986148	Unknown	0.6 mg/kg	Intravenous
Subject	BMS-986148	Unknown	0.8 mg/kg	Intravenous
Subject	BMS-986148	Unknown	1.2 mg/kg	Intravenous
Subject	BMS-986148	Unknown	1.6 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	360 mg	Intravenous

Indications

No indication recorded.